Regional growth engines of thefamilial amyloid cardiomyopathy treatment
On the basis of regionalsegmentation, the FamilialAmyloid Cardiomyopathy Market can be segmented into North America, Europe,Asia Pacific, Latin America, Middle East, and Africa. According to BioMedCentral journal’s published data in year March 2017, Europeans had highestnumber of TTR mutations, followed by East Asians, American, Central-SouthAsians, and Africans which favors the growth of familial amyloid cardiomyopathymarket.
Aggregation and deposition ofmutant and wild-type transthyretin protein (TTR) in heart results in familialamyloid cardiomyopathy, which typically occur after age of 60. Familial amyloidcardiomyopathy is also known as hereditary cardiac transthyretin amyloidosis orhereditary amyloid cardiomyopathy. The protein transthyretin amyloid fibrilsinfiltrate the myocardium that leads to diastolic dysfunction from restrictivecardiomyopathy, which eventually result to heart failure. There are severalmutation in TTR which are associated with familial amyloid cardiomyopathy,which includes V1221, P24S, V20I, A45T, Gly47Val, Glu51Gly, Gln92Lys, I68L, andL111M. Most common mutation is V1221, which is substitution of isoleucine for valineat position 122 that occurs in high frequency in African-Americans, whichfavors the growth of familial amyloid cardiomyopathy treatment market.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/684
European Medicines Agency haveapproved drug named tafamids (Vyndaqel) for slow progression of familial amyloidcardiomyopathy in year 2013 which is expected to favor the market of familialamyloid cardiomyopathy treatment. Most of the pharmaceuticals companies aredeveloping drugs for familial amyloid cardiomyopathy treatment, as it isassociated with progressive heart failure and it is universally fatal. Symptomsfor familial amyloid cardiomyopathy are weight loss, nausea, fatigue, dizzinessand collapse, palpitations, abnormal heart rhythms, disrupted sleep, andangina. Genetic tests are recommended for detection of TTR gene.
Rise in amount of transthyretinprotein in the body fuels the familial amyloid cardiomyopathy treatment market
Transthyretin protein is formedin the body abundantly due to inherited transthyretin gene alteration, whichleads to familial amyloid cardiomyopathy as gene associated transcribes theprotein. Gene alteration in body leads to alteration in sequence of bodyproteins. Familial amyloid cardiomyopathy are inherited by autosomal dominantallele, which can inherit the familial amyloid cardiomyopathy condition tooffsprings from one of the parent. Only one copy of mutated gene is sufficientto cause the disease, which is expected to show growth in the familial amyloidcardiomyopathy market. Familial amyloid cardiomyopathy is critical diseaseleading to heart failure, which can favor the market. According to AmyloidosisFoundation (AF), which provides early diagnosis and advanced treatment,familial amyloid cardiomyopathy are rarely found with statistics estimating 1per 100,000 population suffering from familial amyloid cardiomyopathy disease.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/familial-amyloid-cardiomyopathy-treatment-market-684
The key players dominating thefamilial amyloid cardiomyopathy market
Familial amyloid cardiomyopathynot only affect lives of people but also affect upcoming generations, due towhich manufactures are in process of releasing the drugs, as there are very fewdrugs approved for familial amyloid cardiomyopathy treatment. Recently in June2017 the U.S. Food and Drug Administration (FDA), which provides accurate,science-based health information to the public, granted fast track designationto tafamidis the company’s investigational treatment for familial amyloidcardiomyopathy as there were no approved treatment in the U.S. tafamidis withtrade name VYNDAQEL® was first approved in Europe. The key players operating themarket are Pfizer Inc., SOM Innovation Biotech, S.L., Valeant PharmaceuticalsInternational, Inc., Ionis Pharmaceuticals, Inc., and AstraZeneca plc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/684
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
